"Imatinib Mesylate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.
| Descriptor ID |
D000068877
|
| MeSH Number(s) |
D02.065.277.456 D02.241.223.100.100.435 D02.455.426.559.389.127.085.465 D03.383.606.405 D03.383.742.349
|
| Concept/Terms |
Imatinib Mesylate- Imatinib Mesylate
- Mesylate, Imatinib
- Imatinib Methanesulfonate
- Methanesulfonate, Imatinib
Imatinib- Imatinib
- Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
|
Below are MeSH descriptors whose meaning is more general than "Imatinib Mesylate".
Below are MeSH descriptors whose meaning is more specific than "Imatinib Mesylate".
This graph shows the total number of publications written about "Imatinib Mesylate" by people in this website by year, and whether "Imatinib Mesylate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 3 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 18 | 1 | 19 |
| 2018 | 8 | 5 | 13 |
| 2019 | 2 | 2 | 4 |
| 2020 | 1 | 4 | 5 |
| 2021 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Imatinib Mesylate" by people in Profiles.
-
Antibody formation against SARS-CoV-2 in imatinib-treated COVID-19 patients. J Infect. 2022 02; 84(2):248-288.
-
WHO relaunches global drug trial with three new candidates. Science. 2021 08 06; 373(6555):606-607.
-
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2. Antiviral Res. 2021 09; 193:105137.
-
Imatinib (STI571) Inhibits the Expression of Angiotensin-Converting Enzyme 2 and Cell Entry of the SARS-CoV-2-Derived Pseudotyped Viral Particles. Int J Mol Sci. 2021 Jun 28; 22(13).
-
Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respir Med. 2021 09; 9(9):957-968.
-
Imatinib in COVID-19: hope and caution. Lancet Respir Med. 2021 09; 9(9):938-939.
-
Antiviral drug design based on the opening mechanism of spike glycoprotein in SARS-CoV-2. Phys Chem Chem Phys. 2021 Jun 09; 23(22):12549-12558.
-
[Antineoplasic drug repurposing in hematology for COVID-19 treatment]. Bull Cancer. 2021 Apr; 108(4):435-437.
-
Early clinical experience with imatinib in COVID-19: Searching for a dual effect. J Infect. 2021 05; 82(5):186-230.
-
The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitro. Basic Clin Pharmacol Toxicol. 2021 Apr; 128(4):621-624.